Loading…
JBIO
Jade Biosciences, Inc.
NASDAQ· Healthcare· Biotechnology
$20.84-2.11%
Key metrics
- Market cap
- $1.33B
- P/E
- —
- Forward P/E
- —
- P/B
- 3.0x
- Dividend yield
- —
- EPS
- -$1.05
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $28.00
- 52-week low
- $6.91
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- 55
- Waltham, United States
Company description provided by Yahoo Finance.